Addus HomeCare Corp has a consensus price target of $105, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Macquarie, TD Cowen, and Oppenheimer on June 28, 2024, June 18, 2024, and June 7, 2024. With an average price target of $131.33 between Macquarie, TD Cowen, and Oppenheimer, there's an implied 12.59% upside for Addus HomeCare Corp from these 3 analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/28/2024 | Buy Now | 16.59% | Macquarie | Tao Qiu | → $136 | Initiates | → Outperform | Get Alert |
06/18/2024 | Buy Now | 9.73% | TD Cowen | Ryan Langston | $119 → $128 | Maintains | Buy | Get Alert |
06/07/2024 | Buy Now | 11.44% | Oppenheimer | Michael Wiederhorn | $118 → $130 | Maintains | Outperform | Get Alert |
05/31/2024 | Buy Now | 9.73% | Stephens & Co. | Scott Fidel | $120 → $128 | Maintains | Overweight | Get Alert |
05/09/2024 | Buy Now | 2.01% | TD Cowen | Ryan Langston | $105 → $119 | Maintains | Buy | Get Alert |
05/07/2024 | Buy Now | -1.41% | Stephens & Co. | Scott Fidel | → $115 | Reiterates | Overweight → Overweight | Get Alert |
05/07/2024 | Buy Now | 1.16% | B of A Securities | Joanna Gajuk | $115 → $118 | Maintains | Buy | Get Alert |
04/23/2024 | Buy Now | -28.85% | Barclays | Andrew Mok | → $83 | Downgrade | Equal-Weight → Underweight | Get Alert |
03/26/2024 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | $118 → $118 | Maintains | Outperform | Get Alert |
03/06/2024 | Buy Now | -24.56% | Barclays | Andrew Mok | → $88 | Initiates | → Equal-Weight | Get Alert |
02/29/2024 | Buy Now | -12.56% | RBC Capital | Ben Hendrix | → $102 | Reiterates | Outperform → Outperform | Get Alert |
02/05/2024 | Buy Now | — | William Blair | Jared Haase | — | Assumes | → Outperform | Get Alert |
01/17/2024 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
12/12/2023 | Buy Now | -9.99% | TD Cowen | Ryan Langston | → $105 | Initiates | → Outperform | Get Alert |
11/01/2023 | Buy Now | -12.56% | RBC Capital | Ben Hendrix | $109 → $102 | Maintains | Outperform | Get Alert |
11/01/2023 | Buy Now | -9.99% | Stephens & Co. | Scott Fidel | $110 → $105 | Maintains | Overweight | Get Alert |
08/02/2023 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
08/02/2023 | Buy Now | -9.99% | Raymond James | John Ransom | $100 → $105 | Maintains | Outperform | Get Alert |
08/02/2023 | Buy Now | -5.7% | Stephens & Co. | Scott Fidel | $100 → $110 | Maintains | Overweight | Get Alert |
08/01/2023 | Buy Now | -14.27% | Stephens & Co. | Scott Fidel | → $100 | Reiterates | Overweight → Overweight | Get Alert |
06/29/2023 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | $118 → $118 | Reiterates | Outperform → Outperform | Get Alert |
05/26/2023 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
05/05/2023 | Buy Now | -14.27% | Raymond James | John Ransom | $125 → $100 | Maintains | Outperform | Get Alert |
05/03/2023 | Buy Now | -6.56% | RBC Capital | Ben Hendrix | $123 → $109 | Maintains | Outperform | Get Alert |
05/03/2023 | Buy Now | 1.16% | Oppenheimer | Michael Wiederhorn | $130 → $118 | Maintains | Outperform | Get Alert |
05/02/2023 | Buy Now | 5.44% | Stephens & Co. | Scott Fidel | → $123 | Reiterates | → Overweight | Get Alert |
04/05/2023 | Buy Now | 5.44% | Stephens & Co. | Scott Fidel | → $123 | Reiterates | → Overweight | Get Alert |
03/06/2023 | Buy Now | 5.44% | RBC Capital | Ben Hendrix | $121 → $123 | Maintains | Outperform | Get Alert |
11/02/2022 | Buy Now | 3.73% | RBC Capital | Ben Hendrix | $110 → $121 | Maintains | Outperform | Get Alert |
11/02/2022 | Buy Now | 7.16% | Raymond James | John Ransom | $115 → $125 | Maintains | Outperform | Get Alert |
08/03/2022 | Buy Now | -5.7% | RBC Capital | Ben Hendrix | $111 → $110 | Maintains | Outperform | Get Alert |
08/03/2022 | Buy Now | 11.44% | Oppenheimer | Michael Wiederhorn | $135 → $130 | Maintains | Outperform | Get Alert |
06/29/2022 | Buy Now | -13.42% | Stifel | Tao Qiu | → $101 | Initiates | → Buy | Get Alert |
06/21/2022 | Buy Now | -13.42% | Stephens & Co. | Scott Fidel | $110 → $101 | Maintains | Overweight | Get Alert |
05/04/2022 | Buy Now | -4.84% | RBC Capital | Ben Hendrix | $125 → $111 | Maintains | Outperform | Get Alert |
04/13/2022 | Buy Now | -5.7% | B of A Securities | Joanna Gajuk | → $110 | Initiates | → Buy | Get Alert |
03/10/2022 | Buy Now | 7.16% | RBC Capital | Ben Hendrix | $124 → $125 | Maintains | Outperform | Get Alert |
11/03/2021 | Buy Now | 6.3% | RBC Capital | Frank Morgan | — | Maintains | Outperform | Get Alert |
08/04/2021 | Buy Now | -1.41% | Raymond James | John Ransom | — | Maintains | Outperform | Get Alert |
The latest price target for Addus HomeCare (NASDAQ:ADUS) was reported by Macquarie on June 28, 2024. The analyst firm set a price target for $136.00 expecting ADUS to rise to within 12 months (a possible 16.59% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Addus HomeCare (NASDAQ:ADUS) was provided by Macquarie, and Addus HomeCare initiated their outperform rating.
There is no last upgrade for Addus HomeCare
The last downgrade for Addus HomeCare Corp happened on April 23, 2024 when Barclays changed their price target from $88 to $83 for Addus HomeCare Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addus HomeCare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addus HomeCare was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
While ratings are subjective and will change, the latest Addus HomeCare (ADUS) rating was a initiated with a price target of $0.00 to $136.00. The current price Addus HomeCare (ADUS) is trading at is $116.65, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.